(Incorporated in Bermuda with limited liability) （於百慕達註冊成立之有限公司） （Stock Code 股份代號：858） NOTIFICATION LETTER 通知信函 Dear Non-Registered Holder (Note 1) , 13 March 2025 Extrawell Pharmaceutical Holdings Limited (the "Company") — Notice of publication of Circular dated 13 March 2025 and Proxy Form (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communication are available on the Company's website at http://www.extrawell.com.hk and the website of The Stoc ...

（於百慕達註冊成立之有限公司） （Stock Code 股份代號：858） (Incorporated in Bermuda with limited liability) 13 March 2025 Dear Registered Shareholder(s), NOTIFICATION LETTER 通知信函 Extrawell Pharmaceutical Holdings Limited (the "Company") — Notice of publication of Circular dated 13 March 2025 and Proxy Form (the "Current Corporate Communication") The English and Chinese versions of the Current Corporate Communication are now available on the Company's website at http://www.extrawell.com.hk and the website of The Stock Exchange o ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 精優藥業控股有限公司 主席 謝毅 （ 於百慕達註冊成立之有限公司） （股份代號：00858） 股東特別大會通告 茲通告精優藥業控股有限公司（「本公司」）謹訂於二零二五年三月二十八日(星期五 ）上午十 一時正假座香港金鐘道95號統一中心十樓統一會議中心一號會議室舉行股東特別大會，藉 以考慮並酌情通過（ 無論有否修訂）下列決議案為本公司普通決議案： 普通決議案 「 動 議 委 任 永 拓 富 信 會 計 師 事 務 所 有 限 公 司 為 本 公 司 核 數 師 ， 任 期 直 至 本 公 司 下 屆 股 東 週 年大會結束為止，並授權本公司董事會釐定本公司核數師酬金。」 承董事會命 – 2 – 1. 凡有權出席上述大會並於會上投票之本公司股東，均有權以書面方式委派一名或（ 倘其持有兩股或以上 本公司股份（「股份」））多名代表代其出席大會，並於會上投票。受委任代表毋須為本公司股東。 2. 倘為股份之聯名持有 ...

此 乃 要 件 請 即 處 理 閣 下 如 對 本 通函 之 任 何 內 容 或 應 採 取之 行 動 有 任 何 疑 問 ， 應 諮詢 閣 下 之股 票 經 紀 或 其 他 註冊證券交易商、銀行經理、律師、專業會計師或其他專業顧問。 閣 下 如 已 售出 或 轉 讓 名 下 所 有 精優 藥 業 控 股 有 限 公 司之 股 份 ， 應 立 即 將 本通 函 及 隨 附 之 代 表 委 任 表 格送 交 買 方 或 承 讓 人 或經 手 買 賣 或 轉 讓 之 銀行 、 股 票 經 紀 或 其 他代 理 商 ， 以 便 轉 交買方或承讓人。 香 港 交 易 及結 算 所 有 限 公 司 及 香港 聯 合 交 易 所 有 限 公司 對 本 通 函 之 內 容 概不 負 責 ， 對 其 準 確 性 或 完 整性 亦 不 發 表 任 何 聲 明， 並 明 確 表 示 概 不 就因 本 通 函 全 部 或 任 何部 分 內 容 而 產 生 或因倚賴該等內容而引致之任何損失承擔任何責任。 除文義另有所指外，本通函內所用詞彙具有本通函「釋義」一節所界定的相同涵義。 本公司謹訂於二零二五年三月二十八日（ 星期五 ）上午十 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 （ 於百慕達註冊成立之有限公司） （股份代號：00858） 建議委任核數師 本公告乃由精優藥業控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據香港聯 合交易所有限公司（「聯交所」）證券上市規則第13.51 (4)條作出。 審核委員會在評估委任永拓富信為本公司新核數師時已考慮了多項因素，包括但不限於(i) 永 拓 富 信 的 審 核 建 議 ； (ii) 永 拓 富 信 處 理 聯 交 所 上 市 公 司 審 核 工 作 的 經 驗 、 知 識 及 技 術 能 力；(iii)永拓富信相對於本集團的獨立性及客觀性；(iv)永拓富信的資源與能力；及(v)會計 及財務匯報局所頒佈的指引。基於上文所述，董事會及審核委員會已評估並認為永拓富信 具備獨立性、資格、能力及適合擔任本公司核數師。 – 1 – 股東特別大會 茲提述本公司日期為二零二四年八月十二日之公告有關（ 當中包括 ）開元信德會計師事務所 有 ...

(Incorporated in Bermuda with limited liability) （於百慕達註冊成立之有限公司） （Stock Code 股份代號：858） NOTIFICATION LETTER 通知信函 Dear Non-Registered Holder (Note 1) 18 December 2024 Extrawell Pharmaceutical Holdings Limited (the "Company") — Notice of publication of Interim Report 2024/2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at http://www.extrawell.com.hk and the website of The Stock Exchange of Hon ...

(Incorporated in Bermuda with limited liability) （於百慕達註冊成立之有限公司） （Stock Code 股份代號：858） NOTIFICATION LETTER 通知信函 Dear Registered Shareholder(s), Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders on how they wish to exercise their rights or make elections as Shareholders. 18 December 2024 Extrawell Pharmaceutical Holdings Limited (the "Company") — Notice of publication of Interim Report 2024/2025 (the "Current Corporate Communication") The E ...

Financial Performance - Revenue for the six months ended September 30, 2024, was HK$30,792,000, compared to HK$30,141,000 for the same period in 2023, representing a growth of 2.2%[9] - Gross profit decreased to HK$11,812,000 from HK$14,891,000, reflecting a decline of 20.8% year-over-year[9] - Profit before income tax for the period was HK$102,376,000, a significant recovery from a loss of HK$235,795,000 in the previous year[9] - Profit attributable to owners of the Company was HK$100,934,000, compared to a loss of HK$237,725,000 in the same period last year[12] - Total comprehensive income for the period was HK$103,910,000, a turnaround from a total comprehensive loss of HK$240,574,000 in the prior year[13] - Basic earnings per share for the period was HK$4.22, compared to a loss per share of HK$9.95 in the previous year[14] - The Group recorded a profit after tax of about HK$101.5 million in the 2024 Interim Period, a turnaround from a loss of about HK$236.9 million in the 2023 Interim Period[120] - The profit turnaround was mainly due to a non-cash gain of about HK$111.2 million from the fair value change of financial assets, compared to a loss of about HK$225.9 million in the previous period[120] Assets and Liabilities - Total assets increased to HK$1,399,449,000 as of September 30, 2024, compared to HK$1,287,189,000 as of March 31, 2024, representing a growth of approximately 8.7%[4] - Current assets rose to HK$934,770,000, up from HK$177,442,000, indicating a significant increase of approximately 426.5%[4] - Total equity attributable to owners of the Company reached HK$1,216,476,000, an increase from HK$1,113,125,000, reflecting a growth of about 9.3%[7] - Non-current liabilities, including convertible bonds, increased to HK$127,642,000 from HK$117,124,000, marking an increase of approximately 13.0%[7] - Total liabilities decreased to HK$1,399,449,000 from HK$1,287,189,000, indicating a reduction of approximately 8.7%[7] - Cash and bank balances stood at HK$94,107,000, slightly up from HK$93,610,000, indicating a marginal increase of about 0.5%[4] - The outstanding principal amount of the Company's 20-year zero coupon convertible bonds was HK$577.17 million as of September 30, 2024, unchanged from March 31, 2024[139] Investments and Fair Value - Investments in convertible bonds amounted to HK$660,564,000 as of 30 September 2024[29] - The fair value of the Innovative Pharm Bonds at 30 September 2023 is HK$567,611,000, reflecting a change of (HK$290,826,000) in fair value recognized in profit or loss[38] - The fair value at 30 September 2024 is HK$771,793,000, with an unrealized change of HK$111,229,000 since 31 March 2024[40] - The fair value change of the Innovative Pharm Bonds recorded an unrealized gain of about HK$111.2 million in the 2024 Interim Period, compared to an unrealized loss of about HK$225.9 million in the 2023 Interim Period[129] - The fair value hierarchy of unlisted investment funds and unlisted shares is classified as Level 2, with their fair values remaining zero due to net liabilities[110] - The fair value of short-term investments, such as bank structured products, is also classified as Level 2, determined by estimated returns and credit quality[110] - Investments in convertible bonds are classified as Level 3, with fair value determined through management discussions and independent valuation, considering factors like risk-free rates and expected volatility[112] Cash Flow and Operating Activities - Net cash generated from operating activities was HK$119,000, a recovery from cash used of HK$6,380,000 in the same period last year[21] - Cash and cash equivalents at the end of the period increased to HK$94,107,000 from HK$89,786,000 year-over-year[21] - Other income for the period was HK$3,032,000, slightly down from HK$3,137,000 in the previous year[9] Expenses and Costs - The cost of inventories recognized as expenses was HK$6,790,000, an increase from HK$5,938,000 in the same period last year, representing a rise of approximately 14.4%[83] - Staff costs, including directors' emoluments, totaled HK$9,809,000 for the six months ended September 30, 2024, compared to HK$8,977,000 in 2023, marking an increase of about 9.2%[83] - Selling and distribution expenses decreased by about HK$2.3 million or 34.6%, from approximately HK$6.7 million in the 2023 Interim Period to about HK$4.4 million in the 2024 Interim Period[131] - Administrative expenses decreased by about HK$1.1 million or 9.2%, from approximately HK$11.5 million in the 2023 Interim Period to about HK$10.4 million in the 2024 Interim Period[132] Market and Economic Environment - The Group's operating environment in the pharmaceutical manufacturing sector is increasingly challenging due to structural transformations and regulatory changes in China's medical and health system[120] - China's economy recorded a growth of 4.8% year-on-year in the first three quarters of 2024, supported by strong policies and reforms[118] - The Chinese pharmaceutical market continues to witness stable growth, presenting both opportunities and challenges for the Group[124] Corporate Governance and Compliance - The audit committee has reviewed the unaudited condensed consolidated interim financial information and confirmed compliance with current accounting practices in Hong Kong[177] - The remuneration committee oversees the remuneration policies of the group, ensuring alignment with industry standards[178] - The nomination committee is responsible for formulating and implementing policies for nominating candidates for election by shareholders[179] - The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers, ensuring compliance by its directors throughout the 2024 Interim Period[158] Share Capital and Dividends - The Company has not established a dividend policy, preferring to determine dividend payments based on financial performance and market conditions[156] - The company did not recommend the payment of an interim dividend for the six months ended 30 September 2024, consistent with no dividend declared for the same period in 2023[91] - As of September 30, 2024, the Company had a total of 2,390,000,000 shares issued, with potential conversion rights indicating that UG International could hold approximately 27.36% of the enlarged share capital[164] Employment and Staff - As of 30 September 2024, the Group employed 162 staff, a decrease from 169 employees as of 30 September 2023[150] - Staff costs for the 2024 Interim Period amounted to approximately HK$10.9 million, up from HK$10.2 million in the 2023 Interim Period, primarily due to increased performance-related rewards[150]

Financial Performance - For the six months ended September 30, 2024, the company reported revenue of HKD 30,792,000, representing an increase from HKD 30,141,000 in the same period last year, which is a growth of approximately 2.2%[14] - The gross profit for the same period was HKD 11,812,000, down from HKD 14,891,000, indicating a decrease of about 20.8%[14] - The company recorded a profit of HKD 101,459,000 for the period, a significant recovery from a loss of HKD 236,913,000 in the previous year[14] - The group recorded a profit before tax of HKD 102,376,000 for the six months ended September 30, 2024, compared to a loss of HKD 235,795,000 in the same period of 2023[64] - The net profit for the six months ended September 30, 2024, was HKD 101,459,000, a significant recovery from a net loss of HKD 236,913,000 in 2023[66] - Other income for the six months ended September 30, 2024, totaled HKD 3,032,000, slightly down from HKD 3,137,000 in 2023[69] - The group reported a fair value gain on convertible bonds of HKD 111,229,000 for the six months ended September 30, 2024, compared to a loss of HKD 225,919,000 in 2023[73] - Basic earnings per share for the six months ended September 30, 2024, were HKD 100,934,000, compared to a loss of HKD 237,725,000 in 2023[79] - The group incurred administrative expenses of HKD 5,092,000 for the six months ended September 30, 2024, slightly down from HKD 5,113,000 in 2023[58] Assets and Liabilities - Total assets as of September 30, 2024, were HKD 1,399,449,000, an increase from HKD 1,287,189,000 as of March 31, 2024, reflecting a growth of approximately 8.7%[9] - The company's equity attributable to owners increased to HKD 1,216,476,000 from HKD 1,113,125,000, marking a rise of about 9.3%[5] - The company reported a net cash position of HKD 934,770,000, significantly up from HKD 177,442,000 in the previous period[10] - The company’s non-current liabilities increased to HKD 132,959,000 from HKD 123,206,000, reflecting a rise of approximately 6.2%[7] - The group's total debt to total assets ratio was 0.09, with total assets of approximately HKD 1,399,400,000 and total liabilities of approximately HKD 130,200,000 as of September 30, 2024[108] Revenue Segments - The manufacturing segment generated revenue of HKD 30,772,000 for the six months ended September 30, 2024, up from HKD 30,135,000 in 2023, reflecting a growth of 2.1%[53] - The trading segment reported revenue of HKD 20,000 for the six months ended September 30, 2024, significantly up from HKD 6,000 in 2023, marking a substantial increase of 233.3%[53] Investments and Fair Value - As of September 30, 2024, the fair value of convertible bond investments was HKD 771,793,000, compared to HKD 660,564,000 as of March 31, 2024, representing an increase of 16.8%[25] - The fair value change of convertible bond investments for the six months ended September 30, 2023, showed an unrealized loss of HKD 290,826,000[33] - The fair value of the convertible bonds as of July 12, 2023, was HKD 502,704,000, reflecting a significant valuation adjustment[34] - The company recorded an unrealized gain of approximately HKD 111.2 million from the fair value changes of the convertible bond investment during the interim period of 2024, compared to an unrealized loss of approximately HKD 225.9 million in the same period of 2023[99] Operational Strategies - The company plans to continue expanding its market presence and investing in new product development to drive future growth[22] - The company plans to strengthen internal management and enhance production and sales efficiency to improve market competitiveness and drive profit growth[90] - The company aims to monitor market trends and seize potential long-term development opportunities despite challenges in the pharmaceutical market[91] Employee and Administrative Costs - The employee costs for the interim period amounted to approximately HKD 10,900,000, an increase from HKD 10,200,000 in the same period last year[113] - The company's administrative, sales, and distribution expenses totaled approximately HKD 14,800,000, a decrease of about HKD 3,400,000 or 18.5% compared to HKD 18,200,000 in the previous period[88] - Selling and distribution expenses decreased by approximately HKD 2.3 million or 34.6% to about HKD 4.4 million during the interim period of 2024, due to cost control and increased sales efficiency[102] - Administrative expenses decreased by approximately HKD 1.1 million or 9.2% to about HKD 10.4 million during the interim period of 2024, attributed to streamlined operations and reduced legal and professional fees[103] Dividend Policy - The group did not recommend the payment of an interim dividend for the six months ended September 30, 2024, consistent with no dividend declared for the same period in 2023[78] - The group has no established dividend policy, opting instead to determine dividends based on financial performance and capital needs[118] Staff and Employment - The group employed 162 staff as of September 30, 2024, down from 169 staff a year earlier[113] - The group has not conducted any buybacks, redemptions, or sales of its listed securities during the interim period[120] Compliance and Reporting - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited interim financial information and confirmed compliance with current Hong Kong accounting practices[122] - The interim results announcement has been published on the Hong Kong Stock Exchange and the company's website, with printed copies available upon request[123]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 （股份代號：00858） 盈利預告 本公告乃由精優藥業控股有限公司（「本公司」，連同其附屬公司稱為「本集團」）根據香港聯 合交易所有限公司證券上市規則（「上市規則」）第13.09條及證券及期貨條例第XIVA部（ 香港 法例第571章）項下內幕消息條文（ 定義見上市規則）作出。 本公司董事會（「董事會」）謹此知會本公司之股東（「股東」）及潛在投資者，根據就本集團截 至二零二四年九月三十日止六個月之未經審核綜合管理賬目（「管理賬目」）之初步評估，本 集團預期將錄得盈利介乎100,000,000港元與105,000,000港元之間，而對比截至二零二三年九 月三十日止六個月乃錄得虧損。預期本期內轉虧為盈主要由於非現金項目，因按公平值計 入損益之金融資產（ 即本集團可換股債券投資 ）的公平值變動產生之收益所致，而於二零二 三年相應期間同一非現金項目則錄得公平值變動之虧損。 本公司仍在編製本集團截至二零二四年九月三 ...